Janssen (NYSE:JNJ) has announced positive data from the first randomized controlled trial to test the safety and efficacy of combination therapy with an interleukin (IL)-23p19 subunit antagonist (guselkumab) and a tumor necrosis factor-alpha (TNFα) antagonist (golimumab) in ulcerative colitis. In the Phase 2a VEGA study, 48% of patients who received combination induction therapy with guselkumab and…
Janssen’s guselkumab and golimumab combination fares well in Phase 2a ulcerative colitis study
Johnson & Johnson’s Janssen subsidiary has released positive data from an ongoing analysis of the Phase 2a VEGA clinical study of guselkumab and golimumab. The trial focused on adults with moderately to severely active ulcerative colitis (UC). The study tested the efficacy of 12 weeks of combination induction therapy with the interleukin-23 subunit p19 inhibitor…